LOGC - LogicBio Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

LogicBio Therapeutics, Inc.

610 Main Street
Cambridge, MA 02139
United States
617-245-0399
http://www.logicbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Mr. Frederic ChereauPres, CEO & Director590.87kN/A1967
Dr. Mark A. KayCo-Founder & Director74.69kN/A1958
Dr. Dean A. FalbChief Scientific Officer391.27kN/A1967
Dr. Leszek Lisowski Ph.D.Co-FounderN/AN/AN/A
Dr. Adi BarzelCo-FounderN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

LogicBio Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.